This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Dominique Larrey, MD; Patrick Marcellin, MD; Eric Fréneaux, MD; Dominique Pessayre, MD; Jean-Pierre Benhamou, MD
Hôpital Beaujon Clichy, France

JAMA. 1989;261(14):2065.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Interferons appear to have varying effects on multiple sclerosis according to their major types, designated as alfa, beta, or gamma. The administration of interferon alfa for systemic effect¹ and the intrathecal administration of interferon beta² have been reported to reduce the frequency and severity of exacerbations of multiple sclerosis, possibly because of antiviral properties. In contrast, the disease is exacerbated by administration of interferon gamma, hypothetically because this compound may potentiate immune response.³

Contrary to a previous report,¹ we observed a patient in whom acute exacerbation of multiple sclerosis developed after he received interferon alfa (interferon alfa-2b [Intron A]) for chronic active non-A, non-B hepatitis.

Report of a Case.—

A 38-year-old man was included in a clinical trial assessing the effect of interferon alfa on chronic active non-A, non-B hepatitis in March 1988. The patient had been suffering from multiple sclerosis since 1976. . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?